Cyclizine is a first-generation antihistamine belonging to the piperazine class, primarily used for the prevention and treatment of nausea, vomiting, and motion sickness. It exhibits antiemetic, anticholinergic, and antihistaminic effects by blocking histamine H₁ receptors in the vomiting center and vestibular system. Cyclizine is available in oral and injectable formulations.
Indications include:
∙ Motion sickness
∙ Nausea and vomiting associated with surgery or chemotherapy
∙ Vertigo and vestibular disturbances
∙ Palliative care for nausea and bowel colic (off-label)
Parent: Imatinib / Cyclizine / Piperazine
Parent: Cyclizine Hydrochloride / Cyclizine
Parent: Diphenhydramine/ Ebastine/ Cyclizine/ Dimenhydrinate
Impurities in cyclizine arise from its synthetic pathway, particularly during the formation of piperazine and benzyl derivatives, and from degradation under oxidative, photolytic, or hydrolytic conditions. Due to its use in both oral and parenteral forms, impurity control must follow ICH Q3A/B, USP/EP, and pharmacopeial guidelines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Cyclizine is used to prevent and treat nausea, vomiting, and motion sickness. It’s also used for vestibular disorders and in palliative care settings for symptom relief.
It blocks histamine H₁ receptors and has anticholinergic properties, helping to stabilize the vomiting center and vestibular pathways.
It may be used in children over 6 years with appropriate dosing. Caution is advised in pregnancy; it is Category B (US) but should be used only if clearly needed.
Cyclizine is relatively stable but can degrade under light, heat, or in acidic conditions. It should be stored in a cool, dry, and light-protected container.
